Optimal management of chronic leg ulcers in the elderly.
Chronic leg ulceration is a very common clinical problem in the elderly. Good management depends entirely on making an accurate diagnosis, and planning treatment after considering all aspects of patient well-being. All elderly patients with leg ulcers benefit from an assessment of their vascular status, since the effects of gravity influence treatment and healing irrespective of the diagnosis. The most common causes of ulceration are venous and arterial disease. Diabetes mellitus, pressure, vasculitis, metabolic abnormalities and skin cancer are all unusual causes of leg ulceration, but must be considered in the differential diagnosis. Almost all patients with ulcerated legs benefit from the use of compression bandaging at a level appropriate to their vascular status. In patients with venous ulcers, this can be achieved with a number of bandaging techniques; however, multilayer bandaging appears to be the most cost-effective means available, particularly when combined with community-based leg ulcer clinics. The effects of oral drug therapy for venous and arterial disease have been disappointing. Local dressings are important in ulcers that are not suitable for compression therapy. The choice of dressing depends on the nature of the ulcer and the tolerability of the dressing for the patient.
Goodfield
M
M
Department of Dermatology, General Infirmary, Leeds, England.
D000284:Administration, Oral; D000368:Aged; D000375:Aging / Q000473:pathology*; D001157:Arterial Occlusive Diseases / Q000503:physiopathology; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001458:Bandages; D003131:Combined Modality Therapy; D003920:Diabetes Mellitus / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D007871:Leg Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D008659:Metabolic Diseases / Q000503:physiopathology; D010431:Pentoxifylline / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003668:Pressure Ulcer / Q000503:physiopathology; D016038:Skin Transplantation; D014657:Vasculitis / Q000503:physiopathology; D014689:Venous Insufficiency / Q000503:physiopathology; D014945:Wound Healing / Q000187:drug effects
D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin; D010431:Pentoxifylline